Jump Financial LLC Raises Stake in Recursion Pharmaceuticals, Inc. $RXRX

Key Points

• Jump Financial LLC significantly increased its holdings in Recursion Pharmaceuticals by 4,289.8%, acquiring 578,859 shares, bringing its total to 592,353 shares valued at approximately $3.13 million.
• Brokerages have mixed opinions on Recursion Pharmaceuticals, with Morgan Stanley giving an "equal weight" rating and a price target of $5.00, while Needham has a "buy" rating with a target of $8.00.
• Recursion Pharmaceuticals reported a revenue of $19.10 million for the last quarter, exceeding analysts' expectations but missing EPS estimates, resulting in a net margin of -1,004.91%.

Jump Financial LLC increased its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 4,289.8% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 592,353 shares of the company's stock after acquiring an additional 578,859 shares during the quarter. Jump Financial LLC owned about 0.15% of Recursion Pharmaceuticals worth $3,134,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in RXRX. Softbank Group CORP. acquired a new position in Recursion Pharmaceuticals in the fourth quarter valued at approximately $99,152,000. Novo Holdings A S acquired a new position in Recursion Pharmaceuticals in the fourth quarter valued at approximately $68,375,000. ARK Investment Management LLC lifted its stake in Recursion Pharmaceuticals by 7.6% in the first quarter. ARK Investment Management LLC now owns 34,815,502 shares of the company's stock valued at $184,174,000 after buying an additional 2,469,104 shares during the period. Laurion Capital Management LP acquired a new position in Recursion Pharmaceuticals in the fourth quarter valued at approximately $16,611,000. Finally, Nuveen LLC acquired a new position in Recursion Pharmaceuticals in the first quarter valued at approximately $10,118,000. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Stock Down 3.3%

Shares of NASDAQ:RXRX traded down $0.16 during trading on Friday, reaching $4.70. 15,051,000 shares of the stock were exchanged, compared to its average volume of 17,744,486. The stock has a fifty day moving average of $5.44 and a two-hundred day moving average of $5.65. Recursion Pharmaceuticals, Inc. has a 1-year low of $3.79 and a 1-year high of $12.36. The firm has a market cap of $2.04 billion, a price-to-earnings ratio of -2.64 and a beta of 0.93. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.58 and a quick ratio of 3.58.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.The company had revenue of $19.10 million for the quarter, compared to the consensus estimate of $15.38 million. During the same quarter last year, the company posted ($0.40) EPS. The company's quarterly revenue was up 33.3% compared to the same quarter last year. Research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have issued reports on RXRX shares. Morgan Stanley started coverage on Recursion Pharmaceuticals in a research note on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 price target on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a research report on Tuesday, July 8th. Two equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, Recursion Pharmaceuticals has a consensus rating of "Hold" and a consensus target price of $7.00.

Insider Transactions at Recursion Pharmaceuticals

In other news, insider Najat Khan sold 36,599 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $5.52, for a total transaction of $202,026.48. Following the completion of the transaction, the insider owned 668,197 shares in the company, valued at approximately $3,688,447.44. This represents a 5.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 8.43% of the stock is owned by company insiders.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.